Interstitial

Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Monday, April 15, 2024
Sale, Idiopathic pulmonary fibrosis, Weill Cornell Medicine, University, Internal, Research and development, Epithelium, Investment, Fibroblast, Interstitial, Pleural effusion, IPF, LPE, Intensive care medicine, Administration, University of Giessen, University of Alabama, Patient, Acquisition, Fibrosis, Associate, Series, Therapy, G&A, Critical Care Medicine (journal), ALRN, Pharmaceutical industry

AUSTIN, Texas, April 15, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. (“Aileron”, the “Company”, “we”, “our” or “us”) (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided a business update.

Key Points: 
  • We expect to report topline results from the ongoing Phase 1b study of LTI-03 in the third quarter of this year.
  • Net Loss: Net loss for the quarter ended December 31, 2023, was $7.3 million, compared to $4.5 million for the quarter ended December 31, 2022.
  • The basic and diluted net loss per share for the quarter ended December 31, 2023 was $1.54 compared to $1.00 for the quarter ended December 31, 2022.
  • The basic and diluted net loss per share for the full-year 2023 was $3.42 compared to $6.02 for the full-year 2022.

Aileron Therapeutics to Host Key Opinion Leader Event on February 15, 2024

Retrieved on: 
Thursday, February 1, 2024
University of Giessen, Intensive care medicine, Physician, Therapy, Fibrosis, Aileron, ID, ALRN, Webcast, Interstitial, Internal

WALTHAM, Mass., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. (“Aileron”) (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that it will host a virtual key opinion leader event titled, “Clinical Perspectives on Treating Idiopathic Pulmonary Fibrosis” on Thursday, February 15, 2024, from 4:30 to 5:30 p.m.

Key Points: 
  • WALTHAM, Mass., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. (“Aileron”) (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that it will host a virtual key opinion leader event titled, “Clinical Perspectives on Treating Idiopathic Pulmonary Fibrosis” on Thursday, February 15, 2024, from 4:30 to 5:30 p.m.
  • Aileron management will be joined by pulmonary care medicine experts including:
    Andreas Günther, M.D., Senior Physician of Pulmonology and Intensive Care Medicine and Chief Physician of Pulmonology and Internal Intensive Care Medicine at Agaplesion Evang.
  • To access the event, please dial +1 646-876-9923 (domestic) or +44 208-080-6591 (international) and reference webinar ID: 953 9620 1729 and passcode: 554257 when prompted by the operator.
  • A replay of the webcast will be available following the completion of the event.

Urine Charge! Urology Care Foundation Helps You Keep Your Bladder Healthy for Bladder Health Month

Retrieved on: 
Wednesday, November 1, 2023
Knowledge, Diet, UCF, MD, Woman, UTI, Bladder cancer, Risk, Nocturia, Interstitial, Exercise, Dietary supplement, Birth control

BALTIMORE, Nov. 1, 2023 /PRNewswire/ -- November 1 marks the beginning of Bladder Health Month, and this year, the Urology Care Foundation (UCF) wants you to know 'urine' control of keeping your bladder happy and healthy.

Key Points: 
  • BALTIMORE, Nov. 1, 2023 /PRNewswire/ -- November 1 marks the beginning of Bladder Health Month, and this year, the Urology Care Foundation (UCF) wants you to know 'urine' control of keeping your bladder happy and healthy.
  • Bladder issues are often not talked about because some might feel embarrassed or do not know that it could indicate a health issue.
  • "Promoting awareness of bladder health and urging individuals to engage in discussions with healthcare experts about their bladder health symptoms is a crucial initial measure in eradicating the stigma linked to conditions and diseases related to the bladder," explains Harris M. Nagler, MD, President of the Urology Care Foundation.
  • This lack of information is why every week this month, the Urology Care Foundation will spotlight bladder conditions that impact people in the U.S. and give tips on how to have that important conversation with your doctor.

Glycologix Treats First Patient in Pilot Study of GLX-100 for Treatment of Interstitial Cystitis/Bladder Pain Syndrome

Retrieved on: 
Tuesday, October 24, 2023
Health, Surgery, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, IC/BPS, Nocturia, Pressure, Woman, Safety, Trial of the century, Biopolymer, Patient, Interstitial, Pharmaceutical industry

Glycologix, Inc. (“Glycologix”), a clinical-stage company focused on developing biopolymers for the protection and repair of soft tissues, today announced the treatment of the first patient in a pilot clinical study evaluating GLX-100 as a novel treatment for Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS).

Key Points: 
  • Glycologix, Inc. (“Glycologix”), a clinical-stage company focused on developing biopolymers for the protection and repair of soft tissues, today announced the treatment of the first patient in a pilot clinical study evaluating GLX-100 as a novel treatment for Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS).
  • The multi-center pilot trial is designed to assess the safety, tolerability and effectiveness of GLX-100 in participants with IC/BPS and is expected to enroll up to 40 women with results anticipated in 2024.
  • GLX-100 is a novel biopolymer, which has been designed to closely replicate the natural protective barrier layer and relieve the symptoms of IC/BPS.
  • We look forward to sharing the results from the study in 2024.”

MobileFuse Announces New Ad Unit Suite, Unveils Industry-First Flex-Transparent Interstitial

Retrieved on: 
Tuesday, July 11, 2023
Flex, Advertising, Interstitial, DOOH, CTV, SDK, Mobile phone, Online shopping

NEW YORK, July 11, 2023 /PRNewswire/ -- MobileFuse, one of the largest in-app, CTV, and DOOH advertising platforms, today announced Flex Ad Units, its new ad unit suite comprised of rich media ad formats powered by the MobileFuse SDK. Additionally, it is announcing the first available Flex Ad, Flex-Transparent Interstitial.

Key Points: 
  • NEW YORK, July 11, 2023 /PRNewswire/ -- MobileFuse , one of the largest in-app, CTV, and DOOH advertising platforms, today announced Flex Ad Units, its new ad unit suite comprised of rich media ad formats powered by the MobileFuse SDK.
  • Additionally, it is announcing the first available Flex Ad, Flex-Transparent Interstitial.
  • Flex-Transparent Interstitial is an industry-first offering, bringing immersive full-screen experiences to apps.
  • All apps utilizing the MobileFuse SDK will automatically have access to Flex-Transparent Interstitials, and all future Flex ad units.

Imbrium Therapeutics Completes First Patient Visit in Phase 1 Study of Potential Treatment for Interstitial Cystitis/Bladder Pain Syndrome

Retrieved on: 
Tuesday, December 20, 2022
Biotechnology, FDA, Health, Pharmaceutical, Clinical Trials, Online, Narrative, Trial of the century, Female, Patient, Central nervous system, Treatment, Prevalence, Interstitial, Disease, RA, CDC, Diagnosis, IC/BPS, Veni, vidi, vici, FDA, Safety, Pathology, BPS, PureTech Health, Urinary bladder, Pressure, Pain, Therapy, Effect, Lidocaine, Physician, Research, Pharmaceutical industry, Medical imaging, Woman, Mare Imbrium

Imbrium is a clinical-stage biopharmaceutical company dedicated to advancing medical science through the development of important new pharmacologic and biologic therapeutics.

Key Points: 
  • Imbrium is a clinical-stage biopharmaceutical company dedicated to advancing medical science through the development of important new pharmacologic and biologic therapeutics.
  • Important role of physicians in addressing psychological aspects of interstitial cystitis/bladder pain syndrome (IC/BPS): a qualitative analysis.
  • Beyond a Simple Anesthetic Effect: Lidocaine in the Diagnosis and Treatment of Interstitial Cystitis/bladder Pain Syndrome.
  • Akiyama Y, Homma Y, Maeda D (2019) Pathology and terminology of interstitial cystitis/bladder pain syndrome: a review.

Imbrium Therapeutics Presents Results of a Phase 2 Study of Sunobinop at 33rd American Academy of Addiction Psychiatry Annual Meeting

Retrieved on: 
Monday, December 12, 2022
Science, Biotechnology, Research, Pharmaceutical, Health, FDA, Mental Health, Clinical Trials, Crave, Doctor of Pharmacy, Sleep, Maintenance, Therapy, Interstitial, Physician, M.A, AAAP, Addiction psychiatry, Conditional sentence, Polysomnography, AUD, Central nervous system, Eileen Brooke, American Academy, PSG, Patient, Prevalence, Somnolence, Alcoholism, Architecture, FDA, Peripheral nervous system, Pain, CI, Wakefulness, Journal of Medicinal Chemistry, NOP, PACS, LSM, Safety, Gene–environment correlation, Preclinical development, Overactive bladder, Anxiety, American Academy of Addiction Psychiatry, Kolla, Pharmaceutical industry, Mare Imbrium, Insomnia

The data were presented in a poster presentation (#76) at the 33rd Annual Meeting and Scientific Symposium of the American Academy of Addiction Psychiatry (AAAP).

Key Points: 
  • The data were presented in a poster presentation (#76) at the 33rd Annual Meeting and Scientific Symposium of the American Academy of Addiction Psychiatry (AAAP).
  • Sunobinop is an internally discovered oral compound being evaluated as a potential treatment for multiple disorders including insomnia during recovery from AUD.
  • The Phase 2 randomized, double-blind, multi-center, placebo-controlled, parallel-group clinical study enrolled 114 people experiencing insomnia during recovery from AUD.
  • Imbrium is a clinical-stage biopharmaceutical company dedicated to advancing medical science through the development of important new pharmacologic and biologic therapeutics.

ChannelAdvisor Expands Marketplace and Advertising Channels to Help Brands Drive E-Commerce Growth

Retrieved on: 
Tuesday, October 18, 2022
LinkedIn, NYSE, Managed services, Twitter, ChannelAdvisor, EBay, Automation, Criteo, Blog, Advertising, Walmart, Interstitial, Online shopping, Sales, Google, Facebook, Amazon

Research Triangle Park, N.C., Oct. 18, 2022 /PRNewswire/ --  ChannelAdvisor Corporation (NYSE: ECOM), a leading provider of cloud-based e-commerce solutions that enable brands and retailers to increase global sales, today announced new integrations and platform capabilities to help sellers accelerate their time to market and meet new sources of consumer demand. With these new channel integrations, ChannelAdvisor now supports over 360 marketplaces and retail sites globally, enabling brands and retailers to reach new audiences while expanding their selling footprint.

Key Points: 
  • ChannelAdvisor's integration with the Criteo Retail Media API, supported by ChannelAdvisor's Managed Services team, empowers brands to reach high-intent shoppers on new cookie-less retail channels.
  • Brands seeking new and effective ways to monetize their digital advertising campaigns are increasingly turning to Shoppable Media to help shorten the path to purchase.
  • With this latest release, ChannelAdvisor allows brands to promote multiple products to consumers within a single Buy Now Interstitial experience.
  • For more details about ChannelAdvisor, visit ChannelAdvisor's blog , follow ChannelAdvisor on Twitter @ChannelAdvisor , like ChannelAdvisor on Facebook and connect with ChannelAdvisor on LinkedIn .

PropellerAds Renews ISO/IEC 27001 Information Security Certification

Retrieved on: 
Friday, March 25, 2022
Organization, ISMS, Demography, Information, ISO/IEC 27001, Legislation, Advertising, ISO/IEC, Pop-up ad, Certification, Risk management, Environment, KYC, GDPR, Compliance, Industry, Intellectual property, Information privacy, Interstitial, Medical device, Audit

LIMASSOL, Cyprus, March 25, 2022 /PRNewswire/ -- PropellerAds , an advertising network, announces it has successfully passed an annual surveillance audit and prolonged its ISO/IEC 27001 certification for information security management.

Key Points: 
  • LIMASSOL, Cyprus, March 25, 2022 /PRNewswire/ -- PropellerAds , an advertising network, announces it has successfully passed an annual surveillance audit and prolonged its ISO/IEC 27001 certification for information security management.
  • The ISO/IEC 27001 standard is an internationally recognized specification for an Information Security Management System (ISMS).
  • Its use allows organizations of any type to manage the security of assets such as financial information, intellectual property, employee information, or information entrusted by third parties.
  • Obtaining ISO/IEC 27001 certification is recognized worldwide as evidence that your ISMS complies with best information security practices.

The Urology Care Foundation Urges You to Take Control of Your Bladder Health

Retrieved on: 
Monday, November 1, 2021
Woman, Nocturia, Research, Urinary bladder, Disease, Cancer, Human services, American Urological Association, Twitter, Caregiver, Patient, Office of Inspector General, U.S. Department of Health and Human Services, Bladder cancer, Foundation, Urologic disease, Exercise, Thought, Physician, Instagram, Diet, Facebook, Awareness, Man, Education, Interstitial, Dietary supplement, Medicine

BALTIMORE, Nov. 1, 2021 /PRNewswire/ --November is Bladder Health Awareness Month and while many of us are not always thinking about our bladder health, this month serves as a reminder to get the facts about bladder health conditions and to take an active role in caring for our bladder health.

Key Points: 
  • BALTIMORE, Nov. 1, 2021 /PRNewswire/ --November is Bladder Health Awareness Month and while many of us are not always thinking about our bladder health, this month serves as a reminder to get the facts about bladder health conditions and to take an active role in caring for our bladder health.
  • Each year, millions of men and women struggle with the symptoms related to bladder health conditions or disease.
  • "Raising bladder health awareness and encouraging men and women to talk about their bladder health symptoms is a critical first step in eliminating the stigma associated with bladder-related conditions and disease," said Harris M. Nagler, MD, President of the Urology Care Foundation.
  • About the Urology Care Foundation: The Urology Care Foundation is the world's leading nonprofit urological health foundation, and the official foundation of the American Urological Association.